Review
Oncology
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Summary: Anaplastic lymphoma kinase inhibitors have shown excellent efficacy in treating non-small cell lung cancer patients, with lorlatinib and low-dose alectinib performing well in first-line treatment. Different agents have varying advantages in terms of outcomes, highlighting the need for further large-scale phase III clinical trials to confirm conclusions.
Article
Multidisciplinary Sciences
Anna M. Schlafli, Igor Tokarchuk, Sarah Parejo, Susanne Jutzi, Sabina Berezowska, Nikolai Engedal, Mario P. Tschan
Summary: The study shows that ALK inhibition induces LC3B-independent macroautophagic flux in EML4-ALK(+) cells to support cancer cell survival and clonogenic growth.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Sameera Kumar, Xiaoliang Wang, Harlan Pittell, Gregory S. Calip, Stephanie E. Weiss, Joshua E. Meyer, Trevor J. Royce
Summary: This study investigated the use of CNS-Directed RT in NSCLC patients on first-line ALK inhibitors and found a decreasing trend. The findings suggest that physicians may be deferring upfront local therapy for BM in favor of novel targeted agents with improved CNS activity.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Multidisciplinary Sciences
M. A. Berry, A. R. Bland, J. C. Ashton
Summary: Lung cancer is a major cause of cancer-related deaths. Co-targeting ALK and SHP2 may be an effective strategy for improving drug efficacy. The combination of a SHP2 inhibitor and alectinib can significantly and synergistically suppress the growth of ALK-positive lung cancer cells by regulating the cell cycle and inducing apoptosis.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Laurence Brugieres, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, Julia Arfi-Rouche, Pierre Bories, Anne S. Cottereau, Alain Delmer, Stephane Ducassou, Nathalie Garnier, Laurence Lamant, Amaury Leruste, Frederic Millot, S. Moalla, Franck Morschhauser, Marie Nolla, Anne Pagnier, Yves Reguerre, Loic Renaud, Anne Schmitt, Mathieu Simonin, Arnaud Verschuur, Nathalie Hoog Labouret, Celine Mahier Ait Oukhatar, Gilles Vassal
Summary: The study examined the safety and efficacy of crizotinib in ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL) patients, showing that crizotinib is effective in relapsed/refractory patients, but a large proportion experience relapse after discontinuation. Rating: 8/10.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Bin Wang, Yang Song, Zhuo Chen, Xiaona Su, Xin Yang, Zhi Wei, Junxia Chen, Chuan Chen, Mengxia Li
Summary: This study aimed to investigate the therapeutic effect and safety of ALK inhibitor in ALK-positive lung cancer patients. A total of 59 patients were recruited and divided into two groups: conventional adjuvant chemotherapy and targeted therapy with crizotinib. The results showed that targeted therapy significantly improved disease-free survival (DFS) and overall survival (OS) compared to adjuvant chemotherapy (P < 0.05). Elevated aspartate transaminase/alanine aminotransferase, nausea, and vomiting were the most common adverse events observed.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Yuan Wang, Jing He, Manyu Xu, Qingfeng Xue, Cindy Zhu, Juan Liu, Yaping Zhang, Wenyu Shi
Summary: This review provides an overview of research progress on ALK+ ALCL, including the study of drug resistance mechanisms and the application and development of new therapies. Potential treatment strategies are proposed to guide the design of future clinical trials.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
Summary: The combination of crizotinib with chemotherapy may be effective in ALK-positive and crizotinib sensitive r/r sALCL patients, with significantly improved progression-free survival rates and overall survival rates within two years compared to the control group.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Matthias Fischer, Lucas Moreno, David S. Ziegler, Lynley Marshall, C. Michel Zwaan, Meredith S. Irwin, Michela Casanova, Constantino Sabado, Beate Wulff, Mario Stegert, Luojun Wang, Felipe K. Hurtado, Fabrice Branle, Birgit Geoerger, Johannes H. Schulte
Summary: This study investigated the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. Results showed that the recommended dose for paediatric patients with ALK-positive malignancies is 500 mg/m(2) of ceritinib, which demonstrated promising antitumor activity.
Article
Multidisciplinary Sciences
Yoko Ota, Hiroyuki Yoda, Takahiro Inoue, Takayoshi Watanabe, Yoshinao Shinozaki, Atsushi Takatori, Hiroki Nagase
Summary: The study demonstrates the inhibitory effects of the newly developed ALK inhibitor CCC-003 on cell proliferation in ALK-mutated neuroblastoma, suggesting its potential for treating neuroblastoma and overcoming tyrosine kinase inhibitor resistance. CCC-003 preferentially binds to mutated DNA within the ALK gene and exerts anti-tumor activity through a distinct mode of action compared to other ALK inhibitors.
Article
Medicine, Research & Experimental
Levent Emirzeoglu, Ozgur Olmez
Summary: For certain NSCLC patients, maintaining a complete response to crizotinib treatment may last for more than 6 years, but brain metastases may occur after treatment discontinuation.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2022)
Article
Oncology
Chuquan Shang, Bardes Hassan, Moinul Haque, Yuqi Song, Jing Li, Dongzhe Liu, Eva Lipke, Will Chen, Sylvie Giuriato, Raymond Lai
Summary: The study demonstrated that inhibiting autophagy in ALK + ALCL can increase drug sensitivity in stem-like cells, with differential Myc gene expression playing a critical role in this process. Stem-like cells have a greater impact on the efficacy of therapeutic drugs, indicating their crucial role in drug resistance.
Article
Oncology
Kai Ou, Xiu Liu, Weihua Li, Yi Yang, Jianming Ying, Lin Yang
Summary: This study reported a 34-year-old patient with ALK rearrangement-positive and KRAS-wild pancreatic cancer, who showed significant responses to targeted therapies after developing resistance to chemotherapy, indicating that comprehensive molecular profiling for guiding targeted therapies can significantly improve survival outcomes for a subgroup of patients with pancreatic cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Serena Ceddia, Giovanni Codacci-Pisanelli
Summary: Brain metastases are common in patients with ALK-translocated non-small cell lung cancer and are typically treated with radiotherapy. However, this can lead to severe late toxic side effects, prompting the use of ALK inhibitors such as crizotinib, alectinib, and brigatinib which have shown excellent activity against brain metastases. Starting treatment with specific inhibitors in asymptomatic patients and using radiotherapy when needed provides the best quality of life for patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Oncology
Dan Han, Kewei Zhao, Qin Yang, Liling Zhang, Shihong Fei
Summary: This article presents a case of pituitary metastasis from lung cancer with ALK fusion mutation, and suggests further diagnosis and treatment based on pituitary mass resection and next-generation gene sequencing.
FRONTIERS IN ONCOLOGY
(2022)